Comparison of corneal wound healing rates after instillation of commercially available latanoprost and travoprost in rat debrided corneal epithelium.
ABSTRACT We compared the corneal toxicity of two commercially available anti-glaucoma ophthalmic solutions, travoprost eye drops with sofzia consist of boric acid (H(3)BO(3)) and zinc chloride (ZnCl(2)) and latanoprost eye drops with benzalkonium chloride (BAC), using rat debrided corneal epithelium. Rat corneal epithelium was removed with a BD Micro-Sharp, and the wounded corneas were dyed with a 1% fluorescein solution. The corneal wounds were monitored using a fundus camera TRC-50X equipped with a digital camera. Eye drops were instilled into the rat eyes five times a day after corneal epithelial abrasion. The corneal wound of a rat eye instilled with saline showed 50.9% and 83.4% healing 12 and 24 h after corneal epithelial abrasion, respectively. The healing rate of the corneal wound of a rat eye instilled with travoprost eye drops with sofzia was similar to that of the eye instilled with saline, and this rate was higher than in an eye instilled with latanoprost eye drops with BAC. The rates of corneal wound healing were also lower in eyes instilled with BAC and H3BO3 eye drops than in eyes instilled with saline. In contrast to the results with BAC and H(3)BO(3), the instillation of ZnCl(2) enhanced corneal wound healing in comparison with the instillation of saline The present study demonstrates that the classic preservative system using BAC may be more toxic to rat corneal epithelium than the new preservative system using H(3)BO(3)/ZnCl(2). Travoprost eye drops with sofzia may provide effective therapy for glaucoma patients using long-term ophthalmic agents.
Article: Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients.[show abstract] [hide abstract]
ABSTRACT: To examine the efficacy, safety, and tolerability of travoprost 0.004% benzalkonium chloride (BAK)-free compared with previous use of latanoprost 0.005% in Japanese patients living in the US who had primary open-angle glaucoma or ocular hypertension. This was an open-label, multicenter, bilateral, intraindividual, and active-controlled study in which 20 Japanese American patients with primary open-angle glaucoma or ocular hypertension who had been on latanoprost 0.005% monotherapy were changed to monotherapy with travoprost 0.004% BAK-free daily for 12 weeks. Patients were administered the same series of tests to evaluate the efficacy, safety, and tolerability of latanoprost at the baseline visit and of travoprost BAK-free at the week 12 visit. No significant difference in mean intraocular pressure (IOP) was observed between latanoprost monotherapy at baseline and travoprost BAK-free monotherapy after 12 weeks (P = 0.76), nor were significant differences noted in mean ocular hyperemia, visual acuity, corneal fluorescein staining, or overall scores from the Ocular Surface Disease Index. Patients had a significantly shorter mean tear breakup time while on latanoprost compared with travoprost BAK-free (P = 0.0094). Significantly more patients preferred travoprost BAK-free monotherapy over latanoprost monotherapy (14 versus 6; P = 0.011). The results of this study suggest that Japanese American patients transitioned from latanoprost 0.005% monotherapy to travoprost 0.004% BAK-free can expect similar IOP control and some improvement in anterior segment signs. This transition study showed a strong patient preference for travoprost BAK-free over latanoprost, at a ratio of more than 2:1.Clinical Ophthalmology 01/2010; 4:1355-9.